¼¼°èÀÇ À̸¶Æ¼´Õ(Imatinib) ÀǾàǰ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Çüº°, ¿ëµµº°, Áö¿ªº° ºÐ¼®(2023-2030³â)
Global Imatinib Drug Market Size study & Forecast, by Drug Formulation by Application Type and Regional Analysis, 2023-2030
»óǰÄÚµå : 1363809
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,162,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

À̸¶Æ¼´ÕÀº ƯÁ¤ ¾Ï Ä¡·á¿¡ »ç¿ëµË´Ï´Ù.

À̸¶Æ¼´ÕÀº Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI)·Î ¾Ë·ÁÁø ¾à¹° °è¿­¿¡ ¼ÓÇÕ´Ï´Ù. À̸¶Æ¼´ÕÀº ƯÁ¤ ¾Ï¼¼Æ÷¿¡¼­ »ý¼ºµÇ´Â Ƽ·Î½Å Ű³ª¾ÆÁ¦¶ó´Â ºñÁ¤»óÀûÀÎ ´Ü¹éÁúÀ» ƯÀÌÀûÀ¸·Î Ç¥ÀûÈ­ÇÏ¿© ±× Ȱ¼ºÀ» ¾ïÁ¦ÇÕ´Ï´Ù. À̸¶Æ¼´ÕÀº ÁÖ·Î ºñÁ¤»óÀûÀÎ ¹éÇ÷±¸ °úÀ×»ý¼ºÀ» Ư¡À¸·Î ÇÏ´Â Ç÷¾×¾ÏÀÇ ÀÏÁ¾ÀÎ ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML) Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ, ¼ÒÈ­°ü¿¡ ¹ß»ýÇÏ´Â Á¾¾çÀÇ ÀÏÁ¾ÀÎ ¼ÒÈ­°ü °£ÁúÁ¾¾ç(GIST) Ä¡·á¿¡µµ ó¹æµÇ±âµµ ÇÕ´Ï´Ù. À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀåÀº ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML)°ú ¼ÒÈ­°ü °£ÁúÁ¾¾ç(GIST)ÀÇ ¹ß»ý·ü Áõ°¡, Ç¥ÀûÄ¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

À̸¶Æ¼´ÕÀº ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML) Ä¡·á¿¡ Å« ¼º°øÀ» °ÅµÎ¸ç ³ôÀº ¹ÝÀÀ·ü°ú Àå±âÀûÀÎ ¿¹ÈÄ °³¼±À¸·Î À̾îÁ³½À´Ï´Ù. ±¹¸³ÀÇÇеµ¼­°ü(National Library of Medicine)¿¡ µû¸£¸é, ¼¼°è ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML) À¯º´·üÀº 2020³â 112,000¸í, 2030³â 144,000¸í, 2040³â 167,000¸í, 2050³â 181,000¸í 167,000¸í, 2050³â¿¡´Â 181,000¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼°èÀûÀ¸·Î ¸¸¼º°ñ¼ö¼º¹éÇ÷º´ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í À̸¶Æ¼´Õ ÀǾàǰ °³¹ß°ú °ü·ÃµÈ R&D Ȱµ¿ÀÌ È°¹ßÇØÁö¸é¼­ ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª À̸¶Æ¼´Õ ÀǾàǰÀÇ ³ôÀº ºñ¿ë°ú ´ëüǰÀÇ °¡¿ë¼ºÀº 2023-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

À̸¶Æ¼´Õ ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç, ¾à¹°ÀÇ ½ÅÈï ½ÃÀå °³Ã´, ÀÌ Áö¿ªÀÇ ¾Ï Áúȯ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ 2022³â ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾Ï ¹ßº´·ü Áõ°¡, ½Å¾à°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ½Å¾à°³¹ßÀ» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû/¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ȯ°æ°ú ½ÃÀå »óȲ¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇԵ˴ϴÙ.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

Á¦3Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå ¿ªÇÐ

Á¦4Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå »ê¾÷ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå : Á¦Çüº°

Á¦6Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå : ¿ëµµ À¯Çüº°

Á¦7Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå, Áö¿ª ºÐ¼®

Á¦8Àå °æÀï Á¤º¸

Á¦9Àå Á¶»ç °úÁ¤

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Imatinib drug is used to treat certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Imatinib specifically targets and inhibits the activity of abnormal proteins called tyrosine kinases, which are produced by specific cancer cells. Imatinib is primarily used for the treatment of chronic myeloid leukemia (CML), a type of blood cancer characterized by the overproduction of abnormal white blood cells. It can also be prescribed for the treatment of gastrointestinal stromal tumors (GISTs), a type of tumor that occurs in the gastrointestinal tract. The Imatinib Drug market is expanding because of factors such as Increasing incidence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) and increase in demand for target drug therapy.

Imatinib has demonstrated remarkable success in the treatment of CML, leading to high response rates and improved long-term outcomes. Thus, Rising prevelance of chronic myeloid leukemia is driving the market growth. According to National Library of Medicine, The prevalence of chronic myeloid leukemia (CML) across the globe is 112,000 in year 2020, and it is projected to increase to 144,000 by year 2030, and 167,000 cased by year 2040 and 181,000 cases by year 2050. The rising prevelance of chronic myeloid leukemia across the globe is driving the market growth. In addition, rise in healthcare expenditure and increasing R&D activities related to imatinib drug development is creating a lucrative opportunity in the market. However, high cost of imatinib drug and availability of substitutes stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Imatinib Drug Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in year 2022 owing to presence of key market players, rising development of drug, rising prevelance of cancer disease in the region. Whereas Asia Pacific is witnessing a significant growth owing to factors such as rising prevelance of cancer in the region, rising investment in drug discovery activities, rising government initiatives for promoting drug development activities.

Major market player included in this report are:

Recent Developments in the Market:

Global Imatinib Drug Market Report Scope:

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Formulation offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Formulation:

By Application Type:

By Region:

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Global Imatinib Drug Market Definition and Scope

Chapter 3. Global Imatinib Drug Market Dynamics

Chapter 4. Global Imatinib Drug Market Industry Analysis

Chapter 5. Global Imatinib Drug Market, by Drug Formulation

Chapter 6. Global Imatinib Drug Market, by Application Type

Chapter 7. Global Imatinib Drug Market, Regional Analysis

Chapter 8. Competitive Intelligence

Chapter 9. Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â